{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:23:53Z","timestamp":1793931833085,"version":"4.8.0"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Mycosis fungoides (MF) and S\u00e9zary syndrome (SS) are forms of cutaneous T cell lymphoma (CTCL) that pose significant challenges in their clinical management, particularly in refractory and advanced-stage disease. With the emergence of novel therapeutic modalities however, there are increasing opportunities to exploit the current understanding of pathophysiologic mechanisms of MF\/SS for treatment. This review summarizes recent advances in the treatment of MF\/SS, with a focus on monoclonal antibodies, immunotherapies, and Janus kinase (JAK) inhibitors, including ongoing clinical trials.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1291259","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T09:05:51Z","timestamp":1699002351000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Advancements in the treatment of mycosis fungoides and S\u00e9zary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors"],"prefix":"10.3389","volume":"14","author":[{"given":"Iman","family":"Quadri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Reneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Hanel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine G.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2022.029","article-title":"The treatment of advanced-stage mycosis fungoides and sezary syndrome: a hematologist's point of view","volume":"14","author":"Giordano","year":"2022","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.7.2212","article-title":"Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas","volume":"95","author":"Vergier","year":"2000","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"B4","article-title":"Monoclonal antibodies","volume-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","year":""},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2017.1369951","article-title":"Monoclonal antibodies against cutaneous T-cell lymphomas","volume":"17","author":"Alaibac","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"B6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/1756285614563522","article-title":"Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use","volume":"8","author":"Havrdova","year":"2015","journal-title":"Ther Adv Neurol Disord"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2007.0269","article-title":"Alemtuzumab in S\u00e9zary syndrome: efficient but not innocent","volume":"17","author":"Ure","year":"2007","journal-title":"Eur J Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/art.39132","article-title":"International consensus guidance statement on the management and treatment of igG4-related disease","volume":"67","author":"Khosroshahi","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1385\/MO:19:2S:S27","article-title":"Alemtuzumab in T-cell Malignancies","author":"Dearden","year":"2002","journal-title":"Med Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2802","article-title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/Sezary syndrome","volume":"101","author":"Lundin","year":"2003","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12690","article-title":"Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas","volume":"170","author":"de Masson","year":"2014","journal-title":"Br J Dermatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2165\/00128071-200001010-00008","article-title":"Denileukin diftitox","volume":"1","author":"Figgitt","year":"2000","journal-title":"Am J Clin Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V108.11.696.696","article-title":"Phase III study of denileukin diftitox (ONTAK\u00ae) to evaluate efficacy and safety in CD25+ and CD25- cutaneous T-cell lymphoma (CTCL) patients","volume":"108","author":"Negro-Vilar","year":"2006","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.2.376","article-title":"Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma","volume":"19","author":"Olsen","year":"2001","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3109\/10428194.2012.706286","article-title":"Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and S\u00e9zary syndrome","volume":"54","author":"Prince","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.2386","article-title":"Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma","volume":"28","author":"Prince","year":"2010","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-166916","article-title":"Efficacy and Safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302","volume":"140","author":"Foss","year":"2022","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2165\/11631090-000000000-00000","article-title":"Mogamulizumab: first global approval","volume":"72","author":"Subramaniam","year":"2012","journal-title":"Drugs"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-011-0941-5","article-title":"Antibody therapy for Adult T-cell leukemia-lymphoma","volume":"94","author":"Ishida","year":"2011","journal-title":"Int J Hematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2002.19610.x","article-title":"Increased CCR4 expression in cutaneous T cell lymphoma","volume":"119","author":"Ferenczi","year":"2002","journal-title":"J Invest Dermatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.5.1505","article-title":"Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1\u2013transformed T cells","volume":"99","author":"Yoshie","year":"2002","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"419","DOI":"10.4103\/0019-5154.160511","article-title":"Vorinostat-an overview","volume":"60","author":"Bubna","year":"2015","journal-title":"Indian J Dermatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00236","article-title":"Extracorporeal photopheresis-an overview","volume":"5","author":"Cho","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2015.05.011","article-title":"Extracorporeal photopheresis in the treatment of mycosis fungoides and S\u00e9zary syndrome","volume":"33","author":"Zic","year":"2015","journal-title":"Dermatol Clin"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01794","article-title":"Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study","volume":"41","author":"Sallman","year":"2023","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0137345","article-title":"Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential","volume":"10","author":"Liu","year":"2015","journal-title":"PloS One"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.20230","article-title":"Brentuximab vedotin","volume":"4","author":"van de Donk","year":"2012","journal-title":"mAbs"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2014.1629","article-title":"Brentuximab as a treatment for CD30+ Mycosis fungoides and S\u00e9zary syndrome","volume":"151","author":"Mehra","year":"2015","journal-title":"JAMA Dermatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004710","article-title":"Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data","volume":"5","author":"Horwitz","year":"2021","journal-title":"Blood Adv"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol"},{"key":"B33","article-title":"Ipilimumab and cancer immunotherapy: a new hope for advanced stage melanoma","volume":"84","author":"Mansh","year":"2011","journal-title":"Yale J Biol Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40425-015-0078-9","article-title":"Pembrolizumab","volume":"3","author":"Khoja","year":"2015","journal-title":"J ImmunoTher Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"LBA9000","DOI":"10.1200\/jco.2014.32.15_suppl.lba9000","article-title":"Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL)","volume":"32","author":"Ribas","year":"2014","journal-title":"J Clin Oncol"},{"key":"B36","first-page":"96","article-title":"Keytruda (Pembrolizumab): first PD-1 inhibitor approved for previously treated unresectable or metastatic melanoma","volume":"8","author":"Raedler","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in relapsed and refractory mycosis fungoides and S\u00e9zary syndrome: A multicenter phase II study","volume":"38","author":"Khodadoust","year":"2020","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a Phase ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.183.183","article-title":"A phase 1 study of nivolumab in combination with ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039)","volume":"128","author":"Ansell","year":"2016","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.5114\/ceji.2021.111453","article-title":"Nivolumab in two cases of refractory mycosis fungoides erythroderma","volume":"46","author":"Chmielowska","year":"2021","journal-title":"Cent Eur J Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-786566","article-title":"Duvelisib, a novel oral dual inhibitor of PI3K-\u03b4,\u03b3, is clinically active in advanced hematologic malignancies","volume":"131","author":"Flinn","year":"2018","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.31138\/mjr.31.1.100","article-title":"Basic mechanisms of JAK inhibition","volume":"31","author":"Lin","year":"2020","journal-title":"Mediterr J Rheumatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: The promise of a new drug class","volume":"76","author":"Damsky","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.4445","article-title":"Topical ruxolitinib for the treatment of alopecia universalis","volume":"152","author":"Craiglow","year":"2016","journal-title":"JAMA Dermatol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e89776","DOI":"10.1172\/jci.insight.89776","article-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","volume":"1","author":"Kennedy Crispin","year":"2016","journal-title":"JCI Insight"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40364-016-0056-5","article-title":"Ruxolitinib improves symptoms and quality of life in a patient with systemic mastocytosis","volume":"4","author":"Yacoub","year":"2016","journal-title":"Biomark Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2016.10.003","article-title":"Successful treatment of palmoplantar pustulosis with rheumatoid arthritis, with tofacitinib: Impact of this JAK inhibitor on T-cell differentiation","volume":"173","author":"Koga","year":"2016","journal-title":"Clin Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.2217\/fon.14.272","article-title":"Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis","volume":"11","author":"Arana Yi","year":"2015","journal-title":"Future Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.132837","article-title":"Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma","volume":"100","author":"P\u00e9rez","year":"2015","journal-title":"Haematologica"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-504308","article-title":"PLCG1 mutations in cutaneous T-cell lymphomas","volume":"123","author":"Vaqu\u00e9","year":"2014","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-611194","article-title":"Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides","volume":"126","author":"McGirt","year":"2015","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-559542","article-title":"Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia","volume":"124","author":"Kiel","year":"2014","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.006","article-title":"Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma","volume":"27","author":"Crescenzo","year":"2015","journal-title":"Cancer Cell"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013379","article-title":"A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas","volume":"138","author":"Moskowitz","year":"2021","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0248298","article-title":"Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma","volume":"16","author":"Karagianni","year":"2021","journal-title":"PloS One"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2022.10.010","article-title":"A case of erythrodermic mycosis fungoides responding to upadacitinib","volume":"30","author":"Castillo","year":"2022","journal-title":"JAAD Case Rep"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2020.12.010","article-title":"Acceleration of cutaneous T-cell lymphoma following dupilumab administration","volume":"8","author":"Russomanno","year":"2021","journal-title":"JAAD Case Rep"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-023-02652-z","article-title":"Dupilumab-associated mycosis fungoides: a cross-sectional study","volume":"315","author":"Hamp","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000679","article-title":"Mycosis fungoides unmasked by dupilumab treatment in a patient with a history of atopic dermatitis","volume":"32","author":"Ayasse","year":"2021","journal-title":"Dermatitis"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-590398","article-title":"Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation","volume":"125","author":"Geskin","year":"2015","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3390\/dermatopathology9040045","article-title":"Dupilumab-associated mycosis fungoides with a CD8+ Immunophenotype","volume":"9","author":"Park","year":"2022","journal-title":"Dermatopathol (Basel)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1291259\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T09:05:56Z","timestamp":1699002356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1291259\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,3]]},"references-count":61,"alternative-id":["10.3389\/fimmu.2023.1291259"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1291259","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,3]]},"article-number":"1291259"}}